News
SENATOR Newsletter December 2016
SENATOR Group is closed to hit the Christmas recruitment target of 400 patients. Congratulations to all clinical sites and keep enrolling! To get more information please read the whole December Newsletter here.[more]
SENATOR at The Icelandic Society of Internal Medicine Congress 2016
SENATOR team in Iceland did introduce SENATOR at The Icelandic Society of Internal Medicine Congress 2016 at the conference venue Harpan, Reykjavík. Congratulations to Aðalsteinn Guðmundsson, Ástrós Sverrisdóttir, Pétur...[more]
Special editorial on the SENATOR project in Therapeutic Advances in Drug Safety
The scientists involved in SENATOR project published a special editorial on ´The SENATOR project: developing and trialling a novel software engine to optimizemedications and nonpharmacological therapy in older people with...[more]
Huge step towards project success: All 6 clinical sites open to recruitment to phase II of study
SENATOR Consortium is happy to announce that all six clinical sites are now open to recruitment to phase II of study. The marathon has started - keep going![more]
Prof. O´Mahony at the British Hypertension Society in Dublin
On September 20th for the British Hypertension Society held in Dublin Prof. O´Mahony had talk about STOPP/START Criteria, Medication Review & SENATOR trial under the motto “The very first requirement in a hospital is that it...[more]
National Institute for Clinical Excellence (NICE) UK recommends use of STOPP/START
Recently published UK National Institute for Clinical Excellence (NICE) guideline on multi-morbidity NICE Multimorbidity: clinical assessment and management (like NICE guideline #5 published last year) specifically...[more]
100th patient randomised!
100th patient randomised! The 100th patient was just randomised to the SENATOR trial. Congratulations to everyone in the project! Well done to all and keep going so![more]
